Rate of Recurrent Disease, Persistent Disease, and Death after 131I Therapy in Intermediate-Risk Patients
| Population | 1.11–1.85 GBq | ≥3.7 GBq* | P |
| All patients (n = 225) | 24% (20/85) | 28% (39/140) | Not significant |
| T3N0-X (n = 97) | 21% (9/43) | 20% (11/54) | Not significant |
| T1–2N1 and T1–2N0 with aggressive histology (n = 54) | 21% (4/19) | 26% (9/35) | Not significant |
| T3N1 (n = 74) | 30% (7/23) | 37% (19/51) | Not significant |
↵* No mean or median was given. Similar results were presented for remission, biochemical disease, and metastatic disease for the first therapy.